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Articles
Heritability of variation in glycaemic response to metformin: 
a genome-wide complex trait analysis 
Kaixin Zhou, Louise Donnelly, Jian Yang, Miaoxin Li, Harshal Deshmukh, Natalie Van Zuydam, Emma Ahlqvist, 
The Wellcome Trust Case Control Consortium 2*, Chris C Spencer, Leif Groop, Andrew D Morris, Helen M Colhoun, Pak C Sham, Mark I McCarthy, 
Colin N A Palmer, Ewan R Pearson
Summary
Background Metformin is a fi rst-line oral agent used in the treatment of type 2 diabetes, but glycaemic response to 
this drug is highly variable. Understanding the genetic contribution to metformin response might increase the 
possibility of personalising metformin treatment. We aimed to establish the heritability of glycaemic response to 
metformin using the genome-wide complex trait analysis (GCTA) method.
Methods In this GCTA study, we obtained data about HbA1c concentrations before and during metformin treatment 
from patients in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) study, which includes 
a cohort of patients with type 2 diabetes and is linked to comprehensive clinical databases and genome-wide 
association study data. We applied the GCTA method to estimate heritability for four defi nitions of glycaemic response 
to metformin: absolute reduction in HbA1c; proportional reduction in HbA1c; adjusted reduction in HbA1c; and whether 
or not the target on-treatment HbA1c of less than 7% (53 mmol/mol) was achieved, with adjustment for baseline HbA1c 
and known clinical covariates. Chromosome-wise heritability estimation was used to obtain further information 
about the genetic architecture.
Findings 5386 individuals were included in the fi nal dataset, of whom 2085 had enough clinical data to defi ne 
glycaemic response to metformin. The heritability of glycaemic response to metformin varied by response phenotype, 
with a heritability of 34% (95% CI 1–68; p=0·022) for the absolute reduction in HbA1c, adjusted for pretreatment 
HbA1c. Chromosome-wise heritability estimates suggest that the genetic contribution is probably from individual 
variants scattered across the genome, which each have a small to moderate eff ect, rather than from a few loci that 
each have a large eff ect.
Interpretation Glycaemic response to metformin is heritable, thus glycaemic response to metformin is, in part, 
intrinsic to individual biological variation. Further genetic analysis might enable us to make better predictions for 
stratifi ed medicine and to unravel new mechanisms of metformin action.
Funding Wellcome Trust.
Introduction
Metformin is the recommended fi rst-line oral agent for 
the treatment of hyperglycaemia in patients with type 2 
diabetes, with more than 100 million users worldwide. 
Despite its impressive safety record and effi  cacy at the 
population level, the exact mechanism of metformin 
action is still elusive and patients’ glycaemic responses to 
metformin vary considerably.1–3 Understanding the 
source of such variation might help to identify patients 
most likely not to respond to metformin and could help 
to develop more eff ective agents by providing insight into 
the biological mechanism of metformin.
As with other complex traits, glycaemic response to 
metformin is probably determined by the interplay 
between genetic and environmental factors. Clinical 
variables such as BMI, drug adherence, and dosing 
only account for part of the variation.3 Pharmacogenetic 
studies have identifi ed a few variants in genes aff ecting 
metformin action or its pharmacokinetics, yet these 
variants only account for a small fraction of the 
variation in metformin response.4–8 Two possible 
explanations have been suggested for why so little 
genetic contribution to metformin response variability 
has been identifi ed. First, it might be because the 
overall genetic contribution to variation in glycaemic 
response to metformin is low, with variation mainly 
due to environmental factors; in this case, trying to 
improve understanding of the genetic and biological 
variation in metformin response would have little 
value. A second explanation is that variation in response 
to metformin does have a large genetic component, but 
so far most of the variants with small to moderate 
eff ects have not been identifi ed in genetic association 
studies because of inadequate statistical power; in this 
case, eff ort and resources should be invested in an 
eff ort to discover the genetic contribution to metformin 
response because it might enable a truly stratifi ed 
approach to treatment with this drug. Estimation of the 
extent of genetic contribution to glycaemic response to 
metformin—often termed heritability—is of key 
importance to understand which of these explanations 
is correct.
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See Online for appendix Historically, the heritability of drug response has rarely 
been established, largely because of the impracticality of 
applying the traditional twin and family study designs to 
drug-response phenotypes; assembling suffi  cient family 
members with the same diagnosis who have received the 
same medication and have been assessed using the same 
treatment outcome is all but impossible. Alternative 
methods using population-based genome-wide asso-
ciation study (GWAS) data for heritability estimation have 
been developed.9–11 One of these methods, genome-wide 
complex trait analysis (GCTA), can estimate the distant 
genetic relationship between unrelated individuals using 
GWAS single-nucleotide poly mor phism (SNP) data and 
can correlate the genetic similarity to the phenotypic 
similarity, thus partitioning the total phenotypic variance 
into genetic and environmental causes. Since modern 
GWAS arrays have good coverage of most common 
variants in the human genome, the genetic variance 
estimated by the GCTA method—often referred to as chip 
heritability—is a good indicator of the additive genetic 
contribution from common SNPs.12 Because of the 
insuffi  cient coverage of rare variants on GWAS arrays, 
heritability estimates by the GCTA method are often lower 
than the narrow-sense heritability derived from traditional 
twin and family studies. However, the GCTA method 
off ers a more relevant and accurate estimate of drug-
response heritability than other approaches that have 
been done using cell lines or animal models.13 In this 
study, we apply the GCTA method to GWAS data from the 
Genetics of Diabetes Audit and Research in Tayside 
Scotland (GoDARTS) study14 with the aim of establishing 
the heritability of glycaemic response to metformin.
Methods
Samples
In this GCTA study, we used a bioresource linked to 
electronic health record data (GoDARTS) rather than a 
specifi c cohort developed to assess metformin 
pharmacogenetics. As part of the Wellcome Trust UK 
type 2 diabetes case-control collection, patients with 
type 2 diabetes in Tayside, Scotland, have been invited to 
give written informed consent for DNA collection since 
October, 1997. So far, nearly 10 000 patients with type 2 
diabetes have participated in the GoDARTS study.14 All 
clinical information about these patients can be 
obtained in an anonymised form from SCI-Diabetes (an 
electronic medical record for all patients with diabetes 
in Scotland) and these data are linked to biochemistry 
records and prescription encashments from 1992 
onwards, giving a comprehensive longitudinal record of 
diabetes-related therapy. Participants consented for 
their data to be used in research into diabetes and 
related disorders, and this bioresource was approved by 
Tayside Regional Ethics Committee. The bioresource is 
now governed by Tayside Tissue Bank, which has 
approved the use of the bioresource for the study of 
metformin pharmacogenetics.
Glycaemic response phenotypes  
We used HbA1c concentration, which is a routinely 
measured clinical test of glycaemic control in patients 
with diabetes, to establish glycaemic response to 
metformin (appendix); fasting glucose or other non-
HbA1c measurements of glycaemic control are not 
available in the GoDARTS study. Pretreatment 
(baseline) HbA1c was defi ned as the measurement 
closest to, and within 6 months of, the metformin start 
date (index date), whereas on-treatment HbA1c was 
defi ned as the minimum recorded HbA1c achieved 
within 18 months after the index date. We used four 
diff erent response phenotypes: absolute reduction in 
HbA1c, which was the diff erence between baseline and 
on-treatment HbA1c; proportional reduction in HbA1c, 
which was the absolute reduction divided by baseline 
HbA1c; adjusted reduction in HbA1c, which was the 
residuals of absolute reduction adjusted by known 
clinical covariates such as baseline HbA1c, adherence, 
dose, creatinine clearance, and treatment group; and a 
dichotomous phenotype of whether or not the target 
on-treatment HbA1c of <7% (53 mmol/mol) was 
achieved, with adjustment for baseline HbA1c and 
known clinical covariates.
Patients who received metformin monotherapy used 
no other antidiabetic drugs in the 6 months before the 
index date or during the study period; sulfonylurea 
treatment  was continued throughout the study period in 
patients who used metformin as an add-on therapy. The 
sulfonylurea dose was allowed to vary. Details about how 
the covariates are defi ned, and the response models, are 
outlined in the appendix.
GWAS data and quality control
GWAS data in the GoDARTS cohort were available from 
two previous studies. The Wellcome Trust Case Control 
Consortium 2 study (WTCCC2)8 genotyped 4134 patients 
with the Aff ymetrix 6.0 microarray (Santa Clara, CA, 
USA). The SUrrogate markers for Micro- and Macro-
vascular hard endpoints for Innovative diabetes Tools 
(SUMMIT) study genotyped 3499 patients with the 
Illumina HumanOmniExpress microarray (Illumina, 
San Diego, CA, USA). Imputation to the HapMap3 
panel—a database of common genetic variants that occur 
in human beings—and a stringent quality control 
pipeline were used to combine the two datasets and 
reduce the systematic discrepancy between the genotypes 
produced by the two microarrays and their corresponding 
calling algorithms (appendix).
We did two benchmark analyses with GCTA to validate 
the combined GWAS dataset. The fi rst analysis showed 
that the heritability of human height was 46% (SE 6) in 
this cohort, which was consistent with previous estimates 
by studies applying the GCTA method.15 The second 
analysis estimated the heritability of a pseudo case-
control phenotype assuming that samples from one 
genotyping platform were cases and those from the other 
For more on the HapMap 
project see http://hapmap.ncbi.
nlm.nih.gov/index.html.en
For more on SUMMIT see http://
www.imi-summit.eu/
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platform were controls. As expected, the estimated 
heritability of this dummy platform phenotype was less 
than 1% (SE 5), confi rming that the original GWAS 
datasets were combined without introduction of artifi cial 
heritability.
Heritability estimation
We used GCTA version 1.11 to calculate the pair-wise 
genetic relationship between individuals and create the 
genetic relationship matrix.13 We then applied principal 
components analysis to all the SNPs to calculate the fi rst 
ten eigenvectors, which we included as covariates in all 
the heritability estimation analyses to control for 
potential population structure. We then estimated 
univariate heritability of each drug-response phenotype 
by the restricted maximum likelihood method in GCTA, 
with sex and age at index date included as covariates.
Additionally, we used a bivariate analysis to jointly 
estimate the heritability of baseline HbA1c concentrations 
and the heritability of on-treatment HbA1c concentrations. 
The most informative parameter estimated from this 
bivariate analysis was the genetic correlation (rg), which 
represents the proportion of variance shared between 
baseline HbA1c and on-treatment HbA1c concentrations 
that was contributed by common genetic determinants. 
The correlation between the residual variance is re, which 
represents, in part, contribution from environmental 
factors.
We established statistical signifi cance using the 
likelihood-ratio test of specifi c hypothesis. We report the 
asymptotic 95% CI, which was calculated as 1·96 times 
the SE. Because the SEs of the parameter estimates were 
derived from fi rst-order Taylor series expansions about 
the likelihood in GCTA, they might be biased for 
moderate study sample sizes,15 which at borderline levels 
of signifi cance explains the discrepancy between p value 
and 95% CI reported.
Role of the funding source
The sponsor had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding authors had full access to all the data 
in the study and had fi nal responsibility for the decision 
to submit for publication.
Results
The combined dataset included 1 150 943 autosomal 
SNPs from 6992 patients. After fi ltering for cryptic 
relatedness, 5386 independent individuals were included 
in the fi nal dataset. Of these, 2085 patients had suffi  cient 
clinical data to defi ne their glycaemic response to 
metformin phenotypes. Table 1 summarises the main 
characteristics of the 2085 patients included in this study 
(for sample selection procedure see appendix), stratifi ed 
by 1465 patients on metformin monotherapy and 
620 patients who received metformin as add-on therapy 
to sulfonylureas.
Heritability (h²) for baseline HbA1c was 29% (95% CI 
–1 to 60; p=0·048 for the null hypothesis of being non-
heritable), increasing to 42% (10–73; p=0·0052) for on-
treatment HbA1c (table 2). Baseline-adjusted on-treatment 
HbA1c had a heritability of 36% (95% CI 4–69; p=0·011). 
Of the four drug-response phenotypes, the model-
adjusted reduction in HbA1c (h²=34%, 95% CI 1–68; 
p=0·022) and the ability to reach target HbA1c (h²=32%, 
–1 to 64; p=0·030) were the most heritable. The heritability 
estimates for absolute reduction in HbA1c (h²=23%, 
95% CI –8 to 54) and proportional reduction in HbA1c 
(h²=20%, 95% CI –11 to 51) were smaller, and were not 
statistically signifi cant (table 2).
To assess whether the genetic contribution to variation 
in response to metformin is driven by a few loci with a 
large eff ect or many loci with small eff ect, we did 
univariate heritability estimations for each chromosome 
separately for the two glycaemic response phenotypes 
that were signifi cantly heritable. The genetic contribution 
to variation in response is distributed across several 
chromosomes (fi gure). When the proportion of variance 
in the model-adjusted reduction in HbA1c attributable to 
Metformin 
monotherapy 
(n=1465)
Metformin plus 
sulfonylureas 
(n=620)
Age, years 61·4 (10·5) 65·4 (9·4)
Men 836 (57%) 390 (63%)
BMI, kg/m2 32·6 (5·6) 29·1 (4·9)
Baseline HbA1c, % 8·7 (1·3) 9·2 (1·3)
Baseline to metformin,* days 18 (29) 21 (30)
On-treatment HbA1c, % 7·0 (1·0) 7·4 (1·1)
Metformin dose, g/day 1·26 (0·47) 1·29 (0·51)
Adherence, % 78·4 (16·6) 78·3 (11·1)
Creatinine clearance, mL/min 96·1 (32·7) 79·5 (27·0)
HbA1c measurements, n 3·9 (1·8) 4·2 (1·9)
Data are mean (SD) or number (%). *Time from baseline measurement of HbA1c to 
initiation of metformin treatment. 
Table 1: Sample characteristics
n Heritability 
(h2)
95% CI p value*
HbA1c concentrations
Baseline HbA1c 2085 29% –1 to 60 0·048
On-treatment HbA1c 2085 42% 10 to 73 0·0052
Adjusted on-treatment HbA1c 2085 36% 4 to 69 0·011
Response phenotypes
Absolute reduction in HbA1c 2085 23% –8 to 54 0·074
Proportional reduction in HbA1c 2085 20% –11 to 51 0·10
Adjusted reduction in HbA1c 2069 34% 1 to 68 0·022
Achieved target HbA1c concentration† 1942 32% –1 to 64 0·030
*p values are from likelihood tests of null hypothesis of heritability being 0. †The sample size was reduced to 1942 because 
some patients had a baseline HbA1c concentration of 7% or lower.
Table 2: Univariate heritability estimates of glycaemic response to metformin
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each chromosome (chromosome-wise heritability) was 
regressed against the chromosome length, we noted a 
signifi cant linear trend (p=0·037) for longer 
chromosomes to explain larger proportions of the 
variance. We also noted a similar trend (p=0·034) for 
achievement of target HbA1c.
Bivariate analysis of baseline and on-treatment HbA1c 
concentrations estimated a moderate genetic correlation 
(rg) of 0·58 (95% CI 0·06–1·09) between these two traits 
(table 3). Likelihood ratio tests showed that the genetic 
correlation was statistically greater than 0 (p=0·053) and 
marginally less than 1 (p=0·097); where 0 would mean 
no genetic correlation and 1 would represent 100% 
genetic correlation.
Discussion
This study is, to our knowledge, the fi rst to show that 
genetic diff erences contribute considerably to the 
variation noted in patients’ glycaemic response to 
metformin (panel). The heritability estimates for the 
frequently used defi nitions of glycaemic response range 
from 20% to 34%, suggesting that genetic variants are 
likely to have an important contribution to variation in 
Point estimate 95% CI
Baseline HbA1c 0·29 –0·02 to 0·60
On-treatment HbA1c 0·42 0·11 to 0·73
rg 0·58 0·06 to 1·09
re 0·28 –0·02 to 0·58
The point estimates of baseline and on-treatment HbA1c are for heritability; 
correlation for rg (genetic) and re (environmental).
Table 3: Bivariate analysis of baseline and on-treatment HbA1c
Figure: Chromosome-wise heritability estimation for glycaemic response to metformin
Chromosome-wise heritability plotted for whether or not the target of on-treatment HbA1c <7% (53 mmol/mol) was achieved (A), and for model-adjusted 
reduction in HbA1c—ie, residuals of absolute reduction adjusted by known clinical covariates (B). The circled numbers show the heritability point estimates of each 
chromosome (sex chromosomes were not included). The solid lines plot the linear regression of chromosome-wise heritability against chromosome length; the 
dotted lines show 95% CI.
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glycaemic response to metformin in patients with type 2 
diabetes. In the context of GCTA estimates for other 
complex traits with well established heritability by family 
or twin studies, the point estimates are similar to GCTA 
estimates for schizophrenia (h²=23% [SE 1]) and 
Alzheimer’s disease (h²=30% [SE 3]),16,17 suggesting that 
genetic variants contribute to the variation in HbA1c 
response to metformin to a similar extent.
We did the chromosome-wise heritability estimation to 
provide information about the genetic architecture of 
glycaemic response to metformin. Clearly, several 
variants across diff erent chromosomes contribute to the 
metformin response variation. The fi nding that the 
contribution by an individual chromosome is 
signifi cantly correlated to its length suggests that on each 
chromosome might be many variants with a small to 
moderate eff ect size rather than a few variants with 
major eff ect. This hypothesis is also supported by results 
of the metformin response GWAS, which reported that 
no individual variant explained a large proportion of the 
variance.8 Notably, the point estimates of chromosome-
wise heritability all have large 95% CIs and the estimates 
for each chromosome vary between the two diff erent 
response phenotypes (fi gure). Thus, individual extreme 
values, such as the estimate of chromosome 1 in the 
analysis of model-adjusted reduction in HbA1c, could 
have had an undue eff ect on the reported trend.
In the univariate GCTA analysis we were able to assess 
whether diff erent metformin response phenotypes are 
heritable. We do not have statistical power to conclude 
that one phenotype is more heritable than another, 
although the point estimates for the heritability of the 
response phenotypes that adjusted for the baseline HbA1c 
were greater than for the unadjusted models. Because 
baseline HbA1c has been well documented to have a 
major eff ect on the absolute reduction phenotype,18 the 
higher heritability estimates for baseline-adjusted 
phenotypes of metformin effi  cacy are likely to be a result 
of the successful adjustment for common environmental 
variance between baseline and on-treatment HbA1c 
measurements. These adjusted phenotypes probably 
best address the pharmacogenetics of metformin when 
considering what factors are associated with the greatest 
reduction in HbA1c for a given HbA1c concentration 
before metformin initiation. An adjusted phenotype was 
used to successfully identify variants near the ATM locus 
that aff ect on-treatment HbA1c but not baseline HbA1c.8 
However, such defi nitions adjusted for baseline HbA1c do 
capture some of the shared genetic component (rg) 
described above, and thus identifi ed variants might 
refl ect not only the response to metformin, but also the 
variance in HbA1c per se. When considering what the 
biological determinants of response to metformin are, a 
better phenotype might be the unadjusted absolute 
reduction in HbA1c because this measure does not 
capture any shared genetic contribution, only the variants 
with diff erential genetic eff ects between the HbA1c before 
and after initiation of metformin treatment.19 Such an 
HbA1c reduction model unadjusted for the baseline 
measure has been used in studies of statin 
pharmacogenetics.20,21 However, the heritability for the 
absolute reduction in HbA1c did not achieve statistical 
signifi cance in our study of response to metformin 
treatment.
We report a new application of the GCTA bivariate 
analysis in this drug-response study. This approach has 
advantages over univariate approaches because it does 
not make assumptions about the response model; rather, 
it uses a quantitative genetic approach to partition 
variance into genetic and environmental fractions that are 
shared and non-shared between two states or traits. The 
idea behind such an analysis is that intervention with 
metformin can change the physiological state of a patient. 
In the pretreatment state, a set of genetic and 
environmental factors determine the HbA1c variation; a 
potentially diff erent set of genetic and environmental 
determinants aff ect the on-treatment state (appendix). 
The bivariate analysis can tell us not only how much of 
the HbA1c variance is genetically determined in each state, 
but also how much of the genetically determined HbA1c 
variance is shared between the two physiological states, as 
estimated by genetic correlation (rg). The shared variants 
that underlie the genetic correlation have the same eff ect 
on HbA1c variation in the two states, and their genetic 
contribution to HbA1c is not changed by metformin 
treatment. Thus an rg of 1 would imply that metformin 
intervention does not change the genetic determinants of 
HbA1c in the pretreatment and on-treatment state—ie, no 
pharmacogenetic eff ect occurs.20 By contrast, a low rg 
would imply that the genetic determinants of HbA1c are 
largely diff erent before and after metformin treatment, 
hence a strong pharmacogenetic eff ect. In our analysis, 
the point estimate for the shared genetic contribution was 
0·58, suggesting that around half of the genetic 
determinants contributing to baseline HbA1c and on-
treatment HbA1c concentrations were shared, with half 
the genetic determinants diff ering between the baseline 
Panel: Research in context
Systematic review
We searched PubMed on Feb 18, 2013, with the search terms 
“heritability” and “metformin”. We did not apply any 
publication date or language restrictions. We found no 
previous reports on the heritability of glycaemic response to 
metformin.
Interpretation
This study is, to our knowledge, the fi rst to establish that 
glycaemic response to metformin is likely to be moderately 
heritable. Enhanced GWAS studies will identify more variants, 
enabling better response predictions to be made, and will 
identify new mechanisms of metformin action in the reduction 
of hyperglycaemia in the treatment of type 2 diabetes.
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and metformin treatment states; however, we do 
acknowledge that the 95% CI precludes a defi nitive 
conclusion of this bivariate analysis. 
A key limitation of this study is the reasonably small 
sample size. However, the GoDARTS GWAS data used are 
from the largest metformin pharmacogenomic cohort 
done so far, including 2085 individuals who received 
metformin. Yet we still noted considerable 95% CIs for the 
heritability and genetic correlation estimates due to the 
limited sample size. Thus, despite having suffi  cient power 
to fi nd that glycaemic response to metformin is a heritable 
trait, we do not have power to establish whether one drug 
response trait is more heritable than another. To do this, 
4450 patients would be needed to statistically diff erentiate 
true heritability of 20% and 34%, which correspond to the 
two extremes of the estimated heritability of our four 
reported phenotypes.22 This shortfall in available data 
emphasises the importance of a consortium eff ort to 
assemble even more GWAS data, which will enable us to 
not only achieve more accurate estimates of heritability, 
but also discover more genetic variants that account for 
this heritability. The Metformin Genetics Consortium 
(MetGen) consists of research groups in Europe and the 
USA that have cohorts available for the study of the 
genetics of metformin. This consortium currently consists 
of about 5600 patients who have received metformin, and 
hopefully in the next 2–3 years additional academic and 
commercial clinical trial data and observational data might 
enable a GWAS of about 8000 individuals. Of note, 
interpretations of the heritability estimates from our 
current GCTA analyses can only be made in the context of 
the SNPs captured by the GWAS arrays. Contributions 
from the rare variants that are poorly covered by the GWAS 
panels will not form part of the heritability estimated by 
GCTA, but will remain in the environmental component. 
The observed environmental (residual) correlation (re) of 
0·28 could be contributed by both environmental factors 
and shared rare genetic variants. Thus sequencing-based 
genomic studies with an emphasis on the rare drug-
response variants are valid irrespective of the heritability 
estimates from GWAS SNPs.
In summary, using GWAS data from 2085 patients 
with type 2 diabetes, our analysis showed that genetic 
variants contributed to the variation in glycaemic 
response to metformin, with the heritability of metformin 
response estimated at up to 34% (95% CI 1–68; p=0·022). 
This result shows that a moderate proportion of the 
variance in glycaemic response is genetic, and represents 
underlying biological diff erences between individuals. 
The variants are likely to have a small-to-moderate eff ect 
and be scattered across the genome. So far, very little of 
the genetic contribution to metformin response has been 
identifi ed; GWAS analyses with larger samples could 
fi nd more genetic variants that enable bette r predictions 
to be made for personalised or stratifi ed medicine, and 
unravel new mechanisms of metformin action in the 
reduction of hyperglycaemia.
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